JMJamie L. March

Jamie L. March

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jamie L. March has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Tina D. Hunter

    CTI Clinical Trial and Consulting Services, Covington, USA

    3 shared publications
  • Julian We Jarman

    Cardiology & Electrophysiology, Heart Rhythm Centre, NIHR Cardiovascular Research Unit, The Royal Brompton Hospital, and National Heart and Lung Institute, Imperial College, London, UK

    2 shared publications
  • Tom Wong

    Cardiology & Electrophysiology, Heart Rhythm Centre, NIHR Cardiovascular Research Unit, The Royal Brompton Hospital, and National Heart and Lung Institute, Imperial College, London, UK

    2 shared publications
  • Vias Markides

    Cardiology Department Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust London UK

    2 shared publications
  • Wajid Hussain

    Cardiology & Electrophysiology, Heart Rhythm Centre, NIHR Cardiovascular Research Unit, The Royal Brompton Hospital, and National Heart and Lung Institute, Imperial College, London, UK

    2 shared publications
  • Candace Gunnarsson

    Gunnarsson Consulting

    1 shared publication

Latest Publications

  • Open Access

    Mortality, stroke, and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts

    by Julian We Jarman, Tina D Hunter, Wajid Hussain, Jamie L March, Tom Wong, Vias Markides

    Background: We sought to determine from key clinical outcomes whether catheter ablation of atrial fibrillation (AF) is associated with increased survival. Methods and results: Using routinely collected hospital data, ablation patients were matched to two control cohorts using direct and propensity score methodology. Four thousand nine hundred ninety-one ablation patients were matched 1:1 with general AF controls without ablation. Five thousand four hundred seven ablation patients were similarly matched to controls who underwent cardioversion. We examined the rates of ischemic stroke or transient ischemic attack (stroke/TIA), heart failure hospitalization, and death. Matched populations had very similar comorbidity profiles, including nearly identical CHA2DS2-VASc risk distribution (p=0.6948 and p=0.8152 vs general AF and cardioversion cohorts). Kaplan–Meier models showed increased survival after ablation for all outcomes compared with both control cohorts (pp=0.0087 for stroke/TIA, pppppp=0.0111 for stroke/TIA; HR=0.4, 95% CI: 0.3–0.6, ppConclusions: Catheter ablation of AF was associated with very significant reductions in mortality, stroke/TIA, and heart failure compared with a matched general AF population and a matched population who underwent cardioversion. Potential confounding of outcomes was minimized by very tight cohort matching.


  • Open Access

    Stroke rates before and after ablation of atrial fibrillation and in propensity-matched controls in the UK

    by Julian We Jarman, Tina D Hunter, Wajid Hussain, Jamie L March, Tom Wong, Vias Markides

    Background: We sought to determine whether catheter ablation of atrial fibrillation (AF) is associated with reduced occurrence of ischemic cerebrovascular events. Methods and results: Using routinely collected hospital data, ablation patients were matched to two control cohorts via direct and propensity score matching. A total of 4,991 ablation patients were matched 1:1 to general AF controls with no ablation, and 5,407 ablation patients were similarly matched to controls who underwent cardioversion. Yearly rates of ischemic stroke or transient ischemic attack (stroke/TIA) before and after an index date were compared between cohorts. Index date was defined as the first ablation, the first cardioversion, or the second AF event in the general AF cohort. Matched populations had very similar demographic and comorbidity profiles, including nearly identical CHA2DS2-VASc risk distribution (p-values 0.6948 and 0.8152 vs general AF and cardioversion cohorts). Statistical models of stroke/TIA risk in the preindex period showed no difference in annual event rates between cohorts (mean±standard error 0.30% ± 0.08% ablation vs 0.28% ± 0.07% general AF, p=0.8292; 0.37% ± 0.09% ablation vs 0.42% ± 0.08% cardioversion, p=0.5198). Postindex models showed significantly lower annual rates of stroke/TIA in ablation patients compared with each control group over 5 years (0.64% ± 0.11% ablation vs 1.84% ± 0.23% general AF, pp=0.0222). Conclusion: Matching resulted in cohorts having the same baseline risks and rates of ischemic cerebrovascular events. After the index date, there were significantly lower yearly event rates in the ablation cohort. These results suggest the divergence in outcome rates stems from variance in the treatment pathways beginning at the index date.


  • Acute safety outcomes in younger and older patients with atrial fibrillation treated with catheter ablation

    by Steven C. Hao, Tina D. Hunter, Candace Gunnarsson, Jamie L. March, Sarah A. White, Joseph A. Ladapo, Matthew R. Reynolds

    Catheter ablation for atrial fibrillation (AF) has been demonstrated to be safe and effective in subsets of patients with AF, but primarily in patients age p = 0.6648). There were no peri-procedural mortalities among the 3,575 index ablation procedures performed in an inpatient setting. Acute safety of catheter ablation for AF in patients ≥65 was consistent with that of younger patients. A prior history of hypertension and stroke was associated with a high risk for complications with AF ablation. These findings in a large, real world population may have implications for Medicare patients with AF.